Correlation and influence of hyperlipidemia and chronic complications in patients with type 2 diabetes mellitus

Muamer Suljic ,
Muamer Suljic
Sefcet Hajrovic ,
Sefcet Hajrovic
Elvira Lukac-Radoncic ,
Elvira Lukac-Radoncic
Amina Mulaosmanovic ,
Amina Mulaosmanovic
Zinaida Sijercic ,
Zinaida Sijercic
Ajisa Hajrovic
Ajisa Hajrovic

Published: 01.12.2015.

Biochemistry

Volume 32, Issue 3 (2016)

pp. 1417-1425;

https://doi.org/10.5937/matmed1603417s

Abstract

prevalence to pandemic proportions, but also because vascular complications. Macrovascular complications (macronagiopathy) in diabetes are reduced to a rapid increase atherosclerosis. In diabetes there is a cooperation of multiple independent risk factors for the development of macrovascular complications. Hyperlipidemia are one, and according to some the most important risk factor for atroskleroze and vascular diseases. Diabetic microangiopathy (microvascular complications) is a process that affects the small blood vessels (arterioles, capillaries and venules) a basic change in the thickening of the basement membrane of the blood vessels due to the accumulation of material, also called PAS - positive material. In the study included 64 patients, a close age, were divided into four test grupe.The first group of subjects, which we did the control group consisted of 12 healthy individuals. The second group did the same number of patients with type 2 diabetes without manifest chronic complications. The third study group consisted of 20 patients with diabetes mellitus with developed microvascular complications.In the fourth study group classified 20 patients suffering from diabetes mellitus type 2 with manifest and dominant macrovascular promenama.Glycemia, glycosylated hemoglobin (HbA1C), triglyceride and cholesrola were determined by standard biochemical procedures. Chronic complications were diagnosed on the basis of medical examination of corresponding specialties and standardized diagnostic procedures. Mean values of cholesterol from four of our test group were highest in the group of patients with diabetic microangiopathy and 6:34 +/- 1.35 mmol / l. A statistically significant difference in the level of cholesterol tested between our group could not be found. Following a statistically significant difference in the level of triglycerides, we found that it exists between the control and the other three groups (p = 0.02). An analysis of covariance was possible to statistically determine the impact of certain relevant parameters, such as blood lipid levels on the occurrence of vascular complications. Found a statistically significant effect of plasma cholesterol levels on the occurrence of micro and macroangiopat. The aim is to determine the incidence of hyperlipidemia in patients with diabetes mellitus type 2, in order to determine the differences in the presence of hyperlipidemia between healthy controls and of the respondents with type 2 diabetes mellitus with and without chronic complications, and to investigate the dependence hyperlipidemia.i chronic complications patients with diabetes mellitus type 2.

Keywords

References

1.
Scandinavian Cardiac Outcomes Trial) 16 . Vrlo su značajni i rezultati ASAP studije(Effect og aggressive versus convetional lipid lowering on atherosclerosis progression in familliar hypercholesterolemia),a koja je prva pokazala regresiju aterosklerotskih promena na karotidnim arterijama 17. 2016;
2.
3.
4.
Beckman J, Lybbi M, P. Diabetes and atherosclerosis:epidemiologi,pathophysiology andmanagmenst. JAMA. 2002;2570–81.
5.
Castelli W. Cardiovasculsar dsease and multifactorila risk:Challenge of the 1980s. Am Hear J. 1983;1191.
6.
Vogel J. The pathological anatomy of the human body. 1947;
7.
Kanel B, Castelli W, Gordon T, Mcnamane P. Serum Cholesterol, Lipoprotein and the Risk of CHD.The Framingam Study. AnnInternMed. 1971;1–12.
8.
Laakso M. Lipids in type 2 diabetes. Semin Vasc Med. 2002;(1):59–66.
9.
Fruchart J. Physiology of lipids and lipoproteins. Prev Cardiol. 1999;119–25.
10.
Pantelinac P. 2005;209–16.
11.
Taskinen M. Diabetic dyslipidemia. Atheroscler Suppl. 2002;347–51.
12.
Lyznicki J, Young D, Rigss J. Obesity: Assesment and Menangmentin Primary care. American Family Physician. 2001;2185–94.
13.
Clinical guidelines on the identification, evaluation, and treatment of overweight andobesity in adults-the evidence report. Obes Res. 1998;(6):515–2095.
14.
randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:4S. Lancet. 1994;1383–9.
15.
Aggresive Lipid-Lowering Thrapy compared with Angioplasty in Stable Coronary Artery Disease. The New England Journal of Medicine. 1999;70–6.
16.
Heart Protection study of cholesterol lowering with simvastatin in 5963 people with diabetes.a randomized placebo-controlled trial. Lancet. 2003;2005–16.
17.
Colhoun H, Betteridge D. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atrovastatin Diabetes Study(CARDS):multicentre randomized placebo-controlled trial. Lancet. 2004;685–596.
18.
Owen O. Collaborative atrovastatin diabetes stud: preliminary results. Int J Clin Pract. 2005;121–3.
19.
Ascot Study. Lancet. 2003;1149–58.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners